ABBV stock news · AbbVie Inc.
Get alerts for ABBV
Follow AbbVie Inc. (ABBV) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ABBVAbbVie increased its 2026 sales forecast to $67.8 billion and raised its dividend.
Good for ABBVAbbVie beat estimates, raised its 2026 sales and profit forecasts, and increased its dividend. Growth in key drugs outweighs declines in Humira, Imbruvica, and aesthetics.
AbbVie Q3 2026 Earnings Call Transcript
Good for ABBVAbbVie beat its third-quarter targets, raised its full-year sales forecast, and increased its dividend. These results point to stronger business prospects.
AbbVie shared its financial results for the third quarter of 2026.
NeutralAbbVie announced third-quarter results, but this filing gives no sales or profit figures. It does not show a clear change in the company's outlook.
The FDA has given the green light for AbbVie's SKYRIZI to be used at home for Crohn's Disease.
Good for ABBVAbbVie won FDA approval for a home-start option for SKYRIZI in Crohn's disease. Easier treatment could help more patients use it, making this positive for AbbVie.
Health Canada says AbbVie's Skyrizi can now be used to treat kids with plaque psoriasis.
Good for ABBVSkyrizi can now be used by eligible young patients in Canada. This added treatment option is favorable for AbbVie.
AbbVie Inc. is changing its Board of Directors and has named Dr. John M. Carethers as a new director.
NeutralAbbVie added an independent director and expanded its board to 13 members. The filing reports no business change, so this does not alter how we read the company.
AbbVie Inc. is adding new board members and appointing Dr. John M. Carethers as a director.
NeutralAbbVie added an independent director to its board. The filing reports no business change, so this is neutral for the company.
On Wednesday, eight out of eleven sectors dropped, while the safer ones did better.
NeutralAbbVie rose with Health Care during a broadly weaker session. The report gives no company-specific business news, so it does not change how we view its prospects.
Eight out of eleven sectors dropped on Wednesday, with Health Care and Consumer Staples doing the best.
NeutralAbbVie rose about 3% as health care led Wednesday, but the article reports no company news, so it does not change the company’s outlook.
Cyclical industries did well in Tuesday's trading, while Health Care struggled behind.
NeutralAbbVie fell 1.15% as health care fell 1.07%. The story reports trading moves, not new company news, so it does not change AbbVie’s outlook.
John Moolenaar is asking the Defense Department to put 120 Chinese schools and tech labs on a funding watchlist.
NeutralLawmakers asked AbbVie for information about clinical trials in China and raised data-protection and research-site concerns. They said there was no evidence of illegal activity or wrongdoing, and the story reports no action against AbbVie, so its outlook is unchanged.
AbbVie stock is getting attention after the FDA gave special approval for its new cancer drug.
Good for ABBVAbbVie received 2 FDA special designations for its cancer drug, which may speed development and review. The drug is still unapproved, but the news is a positive step for its cancer program.
On Wednesday, 9 out of 11 sectors dropped, with safer ones like Health Care doing better.
NeutralAbbVie shares rose 2.14% as health care led the sectors, even as all major averages fell. This session report does not show a change in AbbVie's business outlook.
On Tuesday, nine out of eleven sectors went up, with Utilities and Real Estate doing the best.
NeutralAbbVie shares fell 1.49% in Tuesday trading as the health care sector fell 0.51%. This market recap reports no new AbbVie business news, so it does not change the company’s outlook.
AbbVie Inc. shares details about its earnings and financial health.
Bad for ABBVAbbVie expects research and milestone costs to cut third-quarter profit by $0.11 per share. That added cost weighs on its outlook, though the quarter's figures are not final.
8 Of 11 Sectors Rise Friday As Growth Leads
NeutralAbbVie shares fell 0.14% as health care shares slipped 0.18%. The report gives no new company news, so this does not change how we read AbbVie’s business.
AbbVie shares good news about its eczema and weight-loss treatments.
Good for ABBVAbbVie reported encouraging results for an eczema drug and an early weight-loss drug. The findings strengthen its prospects for developing new treatments, but neither study proves a drug will reach patients.
On Monday, eight out of eleven sectors dropped, but defensive ones like Energy and Health Care did well.
NeutralAbbVie shares rose 0.74% as health care shares gained 0.11%, even as major indexes fell. This one-session report brings no new company news, so it does not change AbbVie’s outlook.
Today, there are big trades happening in 10 health care stocks.
NeutralThe article lists an AbbVie options trade tagged bearish, but reports no change to the company's business. This does not change how we read AbbVie.
Rep. Pete Sessions sold more than $100K in Apple shares, according to a recent report.
NeutralAbbVie: The filing lists a $15,001 - $50,000 sale on 2026-09-14. The article warns congressional sales do not necessarily reflect views about the company, so this does not change AbbVie's outlook.
A Congressman who traded $11.5 million keeps selling stocks, including shares of Alphabet and AbbVie.
NeutralA disclosed Sept. 14 sale of $15,000–$50,000 of AbbVie is small relative to AbbVie's size and could be for tax or legal reasons, so it does not change the company's view.
Rep. Pete Sessions sold as much as $100K in AbbVie stock; here’s what you need to know.
NeutralA congressman sold a modest stake in AbbVie; this single, disclosed sale does not change AbbVie's outlook.
Trump's choice for Surgeon General has investments in tobacco and soda companies while Kennedy fights against sugary drinks and junk food.
NeutralAbbVie (ABBV): The nominee will divest certain pharmaceutical holdings, including AbbVie, if confirmed. One person's planned sale is unlikely to affect AbbVie's business.
AbbVie's medicine cuts down the number of days women suffer from menstrual migraines.
Good for ABBVAbbVie reported positive Phase 3 LUNA results for atogepant, which I read as supportive for the drug's commercial prospects and AbbVie's product lineup.